- Report
- July 2024
- 175 Pages
Global
From €4800EUR$5,000USD£4,005GBP
- Report
- March 2025
- 50 Pages
Global
From €2544EUR$2,650USD£2,123GBP
- Report
- March 2025
- 200 Pages
Global
From €4310EUR$4,490USD£3,597GBP
- Report
- May 2024
- 133 Pages
Global
From €6239EUR$6,499USD£5,206GBP
- Report
- May 2024
- 134 Pages
Global
From €6239EUR$6,499USD£5,206GBP
- Report
- November 2022
- 154 Pages
Global
From €4800EUR$5,000USD£4,005GBP
- Report
- June 2020
- 753 Pages
Global
From €2851EUR$2,970USD£2,379GBP
€3168EUR$3,300USD£2,643GBP
- Report
- November 2023
- 175 Pages
Global
From €4800EUR$5,000USD£4,005GBP
- Report
- March 2021
- 102 Pages
Global
From €4320EUR$4,500USD£3,605GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3120EUR$3,250USD£2,603GBP
- Report
- March 2024
- 200 Pages
Global
From €3984EUR$4,150USD£3,324GBP
- Report
- August 2022
- 115 Pages
Global
From €4560EUR$4,750USD£3,805GBP
- Report
- January 2024
- 278 Pages
Global
€4795EUR$4,995USD£4,001GBP

Lenalidomide is an immunomodulatory drug used in the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. It is a derivative of thalidomide, and works by inhibiting tumor growth and angiogenesis. Lenalidomide is also used to treat anemia, a common symptom of cancer. It is taken orally, and is available in both capsule and tablet form.
Lenalidomide is a relatively new drug, and is still in the process of being approved for use in many countries. It is currently approved in the United States, Canada, Europe, Australia, and other countries. It is also being studied for use in other types of cancer, such as breast cancer and non-Hodgkin's lymphoma.
Lenalidomide is a highly effective drug, and is often used in combination with other drugs to treat cancer. It is also used in combination with chemotherapy and radiation therapy.
Lenalidomide is marketed by several companies, including Celgene, Teva Pharmaceuticals, and Mylan. It is also available in generic form from several generic drug manufacturers. Show Less Read more